You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Product menu

Power Reimagined
LIBERATE YOUR PATIENTS FROM DAILY HIV THERAPY

with VOCABRIA + REKAMBYS, the first and only, complete long-acting injectable regimen, dosed once every 2-months, for virologically suppressed patients.1

Indication
Vocabria injection is indicated, in combination with rilpivirine injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.

Introducing: Every 2-Month VOCABRIA (cabotegravir) + REKAMBYS (rilpivirine)

First and only, complete long-acting regimen

First and only, complete long-acting regimen

After initiation, patients will receive their injections once every two months - at total of 6 treatments per year on the continuation phase of treatment1

First and only, complete long-acting regimen

The efficacy you have come to expect from daily HIV regimens

Phase 3 trials established non-inferior efficacy to daily HIV therapy.1-5

First and only, complete long-acting regimen

Preferred by 98% of patients over daily oral therapy in the ATLAS-2M clinical trial

At Week 48, 98% of 306 patients with no prior exposure to VOCABRIA + REKAMBYS who responded to the questionnaire preferred every 2-month injections vs 1% who preferred the study daily oral lead-in (1% reported no preference).5

Request a Contact

SOLAR: First head-to-head data comparing Q2M dosing for HIV-1 vs daily oral therapy

Discover key findings form the SOLAR study

LEARN MORE

References
  1. VOCABRIA Suspension for Injection Summary of Product Characteristics. Available at: https://www.medicines.ie/medicines/vocabria-600-mg-prolonged-release-suspension-for-injection-35220/spc#tabs Last accessed: May 2022.
  2. REKAMBYS Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/rekambys-epar-product-information_en.pdf Last accessed: May 2022.
  3. Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112-1123.
  4. Orkin C, Arasteh K, Hernández-Mora MG, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. Published online ahead of print: March 4, 2020. doi:10.1056/NEJMoa1909512.
  5. Overton ET, Richmond G, Rizzardini G, et al. Cabotegravir + rilpivirine every 2 months is noninferior to monthly dosing: Week 48 results from the ATLAS-2M Study. Presented at Conference on Retroviruses and Opportunistic Infections (CROI): March 8-11, 2020; Boston, MA.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

HIV-1=human immunodeficiency virus type 1.

REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.

All other trademarks are owned by the ViiV Healthcare group, or its licensor. 
©2022 GSK group of companies. All rights reserved.

Date of Preparation: Mar 2023 PM-IE-CBR-WCNT-230001